Cushing's Syndrome - Pipeline Review, H1 2018
Cushing's Syndrome - Pipeline Review, H1 2018
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cushing's Syndrome - Pipeline Review, H1 2018, provides an overview of the Cushing's Syndrome (Metabolic Disorders) pipeline landscape.
Cushing syndrome occurs due to abnormally high levels of the hormone cortisol. The most common cause is overuse of corticosteroid medications. Symptoms of this condition are obesity, glucose intolerance, muscle weakness, bone loss, cognitive dysfunction, depression, and increased urination. Other causes include a pituitary gland tumor and ectopic ACTH syndrome. Treatment includes surgery and medications to control excessive production of cortisol.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cushing's Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cushing's Syndrome (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cushing's Syndrome (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cushing's syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 5 and 2 respectively.
Cushing's Syndrome (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cushing's Syndrome - Pipeline Review, H1 2018, provides an overview of the Cushing's Syndrome (Metabolic Disorders) pipeline landscape.
Cushing syndrome occurs due to abnormally high levels of the hormone cortisol. The most common cause is overuse of corticosteroid medications. Symptoms of this condition are obesity, glucose intolerance, muscle weakness, bone loss, cognitive dysfunction, depression, and increased urination. Other causes include a pituitary gland tumor and ectopic ACTH syndrome. Treatment includes surgery and medications to control excessive production of cortisol.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cushing's Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Cushing's Syndrome (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Cushing's Syndrome (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Cushing's syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 5 and 2 respectively.
Cushing's Syndrome (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Cushing's Syndrome (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Cushing's Syndrome (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cushing's Syndrome (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cushing's Syndrome (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cushing's Syndrome (Metabolic Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cushing's Syndrome (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cushing's Syndrome (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Cushing's Syndrome - Overview
Cushing's Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Cushing's Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cushing's Syndrome - Companies Involved in Therapeutics Development
Angion Biomedica Corp
AstraZeneca Plc
Corcept Therapeutics Inc
Diurnal Group Plc
ElexoPharm GmbH
Hybrigenics SA
Millendo Therapeutics Inc
Novartis AG
Orphagen Pharmaceuticals Inc
Reset Therapeutics Inc
Strongbridge Biopharma plc
Cushing's Syndrome - Drug Profiles
ANG-3563 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit POMC for Cushing’s Syndrome and Cushing Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBX-96819 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levoketoconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nevanimibe hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
osilodrostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relacorilant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CYP11B1 for Cushing's Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Cushing Disease and Psychological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize SF-1 for Cushing's Syndrome, Endometriosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cushing's Syndrome - Dormant Projects
Cushing's Syndrome - Product Development Milestones
Featured News & Press Releases
Apr 04, 2018: SteroTherapeutics Receives FDA Orphan-Drug Designation
Apr 02, 2018: Strongbridge Biopharma Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV (levoketoconazole) in Endogenous Cushing's syndrome
Mar 20, 2018: Strongbridge Biopharma Announces Issuance of Patent for RECORLEV (levoketoconazole) for the Treatment of Cushing’s Syndrome
Mar 18, 2018: Strongbridge Biopharma Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis
Feb 22, 2018: Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial
Jan 18, 2018: Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV (levoketoconazole) for the Treatment of Cushing's Syndrome
Jun 27, 2017: Strongbridge Biopharma Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV (levoketoconazole) in Endogenous Cushing’s Syndrome
Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome
Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for ATR-101 at ENDO 2017
Nov 02, 2016: Millendo Therapeutics to present data on ATR-101 program at Society for Endocrinology British Endocrine Societies Conference
May 31, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the European Congress of Endocrinology
Apr 28, 2016: Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing’s Syndrome and Solid-Tumor Cancers
Apr 04, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the Endocrine Society’s 2016 Annual Conference
Dec 07, 2015: Strongbridge Biopharma Announces Issuance of U.S. Patent for Investigational COR-003 (levoketoconazole) in Treatment of Endogenous Cushing's Syndrome
Oct 13, 2015: Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to be Presented at Annual Meeting of the American Association of Pharmaceutical Scientists
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cushing's Syndrome - Overview
Cushing's Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Cushing's Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cushing's Syndrome - Companies Involved in Therapeutics Development
Angion Biomedica Corp
AstraZeneca Plc
Corcept Therapeutics Inc
Diurnal Group Plc
ElexoPharm GmbH
Hybrigenics SA
Millendo Therapeutics Inc
Novartis AG
Orphagen Pharmaceuticals Inc
Reset Therapeutics Inc
Strongbridge Biopharma plc
Cushing's Syndrome - Drug Profiles
ANG-3563 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotide to Inhibit POMC for Cushing’s Syndrome and Cushing Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZD-4017 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HBX-96819 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
levoketoconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nevanimibe hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
osilodrostat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relacorilant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CYP11B1 for Cushing's Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Cushing Disease and Psychological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize SF-1 for Cushing's Syndrome, Endometriosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cushing's Syndrome - Dormant Projects
Cushing's Syndrome - Product Development Milestones
Featured News & Press Releases
Apr 04, 2018: SteroTherapeutics Receives FDA Orphan-Drug Designation
Apr 02, 2018: Strongbridge Biopharma Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV (levoketoconazole) in Endogenous Cushing's syndrome
Mar 20, 2018: Strongbridge Biopharma Announces Issuance of Patent for RECORLEV (levoketoconazole) for the Treatment of Cushing’s Syndrome
Mar 18, 2018: Strongbridge Biopharma Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis
Feb 22, 2018: Corcept Therapeutics Announces 2017 Financial Results and Positive Interim Results of Relacorilant Phase 2 Trial
Jan 18, 2018: Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV (levoketoconazole) for the Treatment of Cushing's Syndrome
Jun 27, 2017: Strongbridge Biopharma Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV (levoketoconazole) in Endogenous Cushing’s Syndrome
Mar 28, 2017: Millendo Therapeutics Announces Initiation of Phase 2 Clinical Trial of ATR-101 in Patients with Endogenous Cushing's Syndrome
Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for ATR-101 at ENDO 2017
Nov 02, 2016: Millendo Therapeutics to present data on ATR-101 program at Society for Endocrinology British Endocrine Societies Conference
May 31, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the European Congress of Endocrinology
Apr 28, 2016: Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 as Potential Treatment for Cushing’s Syndrome and Solid-Tumor Cancers
Apr 04, 2016: Strongbridge Biopharma Announces Presentation of COR-003 Data at the Endocrine Society’s 2016 Annual Conference
Dec 07, 2015: Strongbridge Biopharma Announces Issuance of U.S. Patent for Investigational COR-003 (levoketoconazole) in Treatment of Endogenous Cushing's Syndrome
Oct 13, 2015: Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to be Presented at Annual Meeting of the American Association of Pharmaceutical Scientists
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development for Cushing's Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Cushing's Syndrome - Pipeline by Angion Biomedica Corp, H1 2018
Cushing's Syndrome - Pipeline by AstraZeneca Plc, H1 2018
Cushing's Syndrome - Pipeline by Corcept Therapeutics Inc, H1 2018
Cushing's Syndrome - Pipeline by Diurnal Group Plc, H1 2018
Cushing's Syndrome - Pipeline by ElexoPharm GmbH, H1 2018
Cushing's Syndrome - Pipeline by Hybrigenics SA, H1 2018
Cushing's Syndrome - Pipeline by Millendo Therapeutics Inc, H1 2018
Cushing's Syndrome - Pipeline by Novartis AG, H1 2018
Cushing's Syndrome - Pipeline by Orphagen Pharmaceuticals Inc, H1 2018
Cushing's Syndrome - Pipeline by Reset Therapeutics Inc, H1 2018
Cushing's Syndrome - Pipeline by Strongbridge Biopharma plc, H1 2018
Cushing's Syndrome - Dormant Projects, H1 2018
Number of Products under Development for Cushing's Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Cushing's Syndrome - Pipeline by Angion Biomedica Corp, H1 2018
Cushing's Syndrome - Pipeline by AstraZeneca Plc, H1 2018
Cushing's Syndrome - Pipeline by Corcept Therapeutics Inc, H1 2018
Cushing's Syndrome - Pipeline by Diurnal Group Plc, H1 2018
Cushing's Syndrome - Pipeline by ElexoPharm GmbH, H1 2018
Cushing's Syndrome - Pipeline by Hybrigenics SA, H1 2018
Cushing's Syndrome - Pipeline by Millendo Therapeutics Inc, H1 2018
Cushing's Syndrome - Pipeline by Novartis AG, H1 2018
Cushing's Syndrome - Pipeline by Orphagen Pharmaceuticals Inc, H1 2018
Cushing's Syndrome - Pipeline by Reset Therapeutics Inc, H1 2018
Cushing's Syndrome - Pipeline by Strongbridge Biopharma plc, H1 2018
Cushing's Syndrome - Dormant Projects, H1 2018
LIST OF FIGURES
Number of Products under Development for Cushing's Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Cushing's Syndrome - Companies Involved in Therapeutics Development
Angion Biomedica Corp
Number of Products under Development for Cushing's Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Cushing's Syndrome - Companies Involved in Therapeutics Development
Angion Biomedica Corp
